Purpose: Critical to the success of active immunotherapy against cancer is the identification
of immunologically recognized cancer-specific proteins with low tolerogenic potential.
Cancer testis antigens (CTA), in particular, fulfill this requirement as a result of their aberrant
expression restricted to cancer cells and lack of expression in normal tissues bypassing
tolerogenic mechanisms against self. Although CTAs have been extensively studied in solid
malignancies, little is known regarding their expression in chronic lymphocytic leukemia …

Critical to success of active immunotherapy against cancer is the identification of
immunologically recognized cancer-specific proteins with low tolerogenic potential. Cancer
testis antigens (CTAs) in particular, fulfill this requirement as a result of their aberrant
expression restricted to cancer cells and lack of expression in normal tissues bypassing
tolerogenic mechanisms against self. Although CTAs have been extensively studied in solid
malignancies little is known regarding their expression in chronic lymphocytic leukemia …